Neuromyelitis optica (NMO, Devic syndrome) and myasthenia gravis (MG) are rare antibody-mediated autoimmune disorders. Concurrent incidence has been reported in only few patients, mostly non-Caucasians.
Objective:
To report on ten Caucasian patients with NMO spectrum disorders (NMOSD) and MG and to provide a comprehensive review of the literature.
Method:
Retrospective study.
Results:
In total, 26 patients (m:f = 1:12; Caucasian in 12) with MG (generalized in 17) and NMOSD (NMO in 21, longitudinally extensive transverse myelitis in five) were identified from the authors’ own files (n = 10) and the previous literature (n = 16). MG preceded NMOSD in 24/25 cases (96%). AQP4-Ab were tested in 20 patients and were positive in 17 (85%). Twenty out of 25 patients (80%) had been treated with thymectomy or thymic irradiation, which preceded NMOSD in all cases (median latency, 12 years; range, 0.3–32). At last follow-up, complete remission of MG was reported in 15/22 (68%), and MG was well controlled with pyridostigmine in three. Co-existing autoimmune disorders or autoimmune antibodies were reported in 17 patients.
Conclusion:
Our study demonstrates that i) AQP4-Ab-positive NMOSD are more commonly associated with MG in Caucasians than previously thought; ii) MG precedes NMOSD in most cases, often by more than a decade; iii) NMOSD almost exclusively occur in females with juvenile or early-onset MG; and iv) MG frequently takes an unusually mild course in patients with NMOSD. A history of thymectomy could be a possible risk factor for the later development of NMOSD. We recommend testing for AQP4-Ab in MG patients presenting with atypical motor or optic symptoms.
JariusSPaulFFranciottaDWatersPZippFHohlfeldR, et al. Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol2008; 4: 202–214.
4.
JariusSWildemannB. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol2010; 6: 383–392.
5.
de SezeJStojkovicTFerribyDGauvritJYMontagneCMounier-VehierF, et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci2002; 197: 57–61.
6.
JariusSFranciottaDBergamaschiRWrightHLittletonEPalaceJ, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology2007; 68: 1076–1077.
7.
LennonVAWingerchukDMKryzerTJPittockSJLucchinettiCFFujiharaK, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet2004; 364: 2106–2112.
8.
LennonVAKryzerTJPittockSJVerkmanASHinsonSR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med2005; 202: 473–477.
9.
PaulFJariusSAktasOBluthnerMBauerOAppelhansH, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med2007; 4: e133.
10.
BradlMMisuTTakahashiTWatanabeMMaderSReindlM, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol2009; 66: 630–643.
11.
BennettJLLamCKalluriSRSaikaliPBautistaKDupreeC, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol2009; 66: 617–629.
12.
SaadounSWatersPBellBAVincentAVerkmanASPapadopoulosMC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain2010; 133: 349–361.
13.
JariusSAboul-EneinFWatersPKuenzBHauserABergerT, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain2008; 131: 3072–3080.
14.
WandingerKPStangelMWitteTVenablesPCharlesPJariusS, et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum2010; 62: 1198–1200.
15.
PittockSJLennonVAde SezeJVermerschPHomburgerHAWingerchukDM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol2008; 65: 78–83.
16.
JariusSJacobiCde SezeJZephirHPaulFFranciottaD, et al. Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler2011; 17: 1067–1073.
17.
WeinshenkerBGWingerchukDMVukusicSLinboLPittockSJLucchinettiCF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol2006; 59: 566–569.
18.
JariusSFrederiksonJWatersPPaulFAkman-DemirGMarignierR, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci2010; 298: 158–162.
19.
WingerchukDMLennonVAPittockSJLucchinettiCFWeinshenkerBG. Revised diagnostic criteria for neuromyelitis optica. Neurology2006; 66: 1485–1489.
20.
AntoineJCCamdessancheJPAbsiLLassabliereFFeassonL. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology2004; 62: 978–980.
21.
BichuettiDBBarrosTMOliveiraEMAnnesMGabbaiAA. Demyelinating disease in patients with myasthenia gravis. Arq Neuropsiquiatr2008; 66: 5–7.
22.
FurukawaYYoshikawaHYachieAYamadaM. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol2006; 13: 655–658.
23.
IkedaKArakiYIwasakiY. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology2007; 68: 1326; author reply 27.
24.
IsbisterCMMackenziePJAndersonDWadeNKOgerJ. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler2003; 9: 550–553.
25.
NakamuraMNakashimaISatoSMiyazawaIFujiharaKItoyamaY. Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Mult Scler2007; 13: 332–335.
26.
KayCSScolaRHLorenzoniPJJariusSArrudaWOWerneckLC. NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci2008; 275: 148–150.
27.
UzawaAMoriMIwaiYKobayashiMHayakawaSKawaguchiN, et al. Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci2009287: 105–107.
28.
KisterIGulatiSBozCBergamaschiRPiccoloGOgerJ, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol2006; 63: 851–856.
29.
GotkineMFelligYAbramskyO. Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology2006; 67: 881-883.30.
30.
O’RiordanJIGallagherHLThompsonAJHowardRSKingsleyDPThompsonEJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry1996; 60: 382–387.
31.
WatersPJariusSLittletonELeiteMIJacobSGrayB, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol2008; 65: 913–919.
32.
ChanKHKwanJSHoPWHoJWChuACRamsdenDB. Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflamm2010; 7: 50.
33.
TakahashiTFujiharaKNakashimaIMisuTMiyazawaINakamuraM, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain2007; 130: 1235–1243.
34.
JariusSProbstCBorowskiKFranciottaDWildemannBStoeckerW, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci2010; 291: 52–56.
35.
JariusSFranciottaDPaulFRuprechtKBergamaschiRRommerPS, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflamm2010; 7: 52.
36.
JariusSPaulFFranciottaDRuprechtKRingelsteinMBergamaschiR, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci2011; 306: 82–90.
37.
AsgariNLillevangSTSkejoeHPFalahMStenagerEKyvikKO. A population-based study of neuromyelitis optica in Caucasians. Neurology2011; 76: 1589–1595.
38.
CarrASCardwellCRMcCarronPOMcConvilleJ. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol2010; 10: 46.
39.
MantegazzaRBaggiFAntozziCConfalonieriPMorandiLBernasconiP, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci2003; 998: 413–423.
40.
AarliJARomiFSkeieGOGilhusNE. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci2003; 998: 424–431.
41.
ChristensenPBJensenTSTsiropoulosISorensenTKjaerMHojer-PedersenE, et al. Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989. Neurology1993; 43: 1779–1783.
McGroganASneddonSde VriesCS. The incidence of myasthenia gravis: a systematic literature review. Neuroepidemiology2010; 34: 171–183.
44.
MevorachDPerrotSBuchananNKhamashtaMLaoussadiSHughesG, et al. Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature. Lupus1995; 4: 33–37.
45.
SantS. Systemic lupus erythematosus after thymectomy in a patient with myasthenia gravis. Ir Med J1997; 90: 116–118.
46.
ZonanaMReyesEWeismanA. Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity. J Clin Rheumatol2002; 8: 322–325.
47.
RosmanAAtsumiTKhamashtaMAmesPHughesG. Development of systemic lupus erythematosus after chemotherapy and radiotherapy for malignant thymoma. Br J Rheumatol1995; 34: 1175–1176.
48.
GerliRPaganelliRCossarizzaAMuscatCPiccoloGBarbieriD, et al. Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol1999; 103: 865–872.
49.
ParambilJKeoghKFervenzaFRyuJ. Microscopic polyangiitis associated with thymoma, exacerbating after thymectomy. Am J Kidney Dis2006; 48: 827–831.
50.
SuzukiSShimodaMKawamuraMSatoHNogawaSTanakaK, et al. Myasthenia gravis accompanied by alopecia areata: clinical and immunogenetic aspects. Eur J Neurol2005; 12: 566–570.
51.
WakataNKiyozukaTKonnoSNakazoraHNomotoNSugimotoH, et al. Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis. Intern Med2006; 45: 479–481.
52.
GonlugurUSahinEYildizEGonlugurTE. Early autoimmune complications after thymomectomy in a patient with interstitial lung disease. Case report. Acta Microbiol Immunol Hung2006; 53: 105–111.
53.
KojimaAPrehnR. Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics1981; 14: 15–27.
54.
ItohMTakahashiTSakaguchiNKuniyasuYShimizuJOtsukaF, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol1999; 162: 5317–5326.
55.
AsanoMTodaMSakaguchiNSakaguchiS. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med1996; 184: 387–396.
56.
ChiYFanYHeLLiuWWenXZhouS, et al. Novel role of aquaporin-4 in CD4(+) CD25(+) T regulatory cell development and severity of Parkinson’s disease. Aging Cell2011; 10: 368–382.
57.
BarrettSTohBAlderuccioFvan DrielIGleesonP. Organ-specific autoimmunity induced by adult thymectomy and cyclophosphamide-induced lymphopenia. Eur J Immunol1995; 25: 238–244.
58.
Schulze-KoopsH. Lymphopenia and autoimmune diseases. Arthritis Res Ther2004; 6: 178–180.
59.
ChanKHKwanJSHoPWHoSLChuiWHChuAC, et al. Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. J Neuroimmunol2010; 227: 178–184.
60.
PittockSJLennonVA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol2008; 65: 629–632.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
